Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Editor, APAC, Pharma Insights
China
9+ years of experience
Scrip
By Brian Yang 27 Nov 2020
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
Topic China Infectious Diseases Policy & Regulation Coronavirus
Medtech Insight
By Brian Yang 27 Nov 2020
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.
Pink Sheet
By Brian Yang 27 Nov 2020
Ex-China FDA Commissioner Bi Jingquan’s new role, a waiver of bioequivalence testing for hundreds of drugs, data accuracy requirements and a new crackdown on compliance issues.
Topic China Regulation Compliance
Pink Sheet
By Brian Yang 27 Nov 2020
A quickly spreading coronavirus outbreak in China could upend the country’s healthcare priorities as the health regulators and reimbursement agency officials gear up to “control and prevent” the worst public health emergency since the deadly SARS outbreak in 2003.
Topic China Coronavirus Infectious Diseases Policy & Regulation
Scrip
By Brian Yang 27 Nov 2020
AbbVie’s HIV therapy Kaletra is now being used by the Chinese government to treat coronavirus-infected patients after a respiratory expert endorsed its use, while other pharma companies from Bayer to Innovent are showering support as China battles its worst virus outbreak since the SARS epidemic 17 years ago.
Pink Sheet
By Brian Yang 18 Nov 2020
Given the ongoing election challenges in the US, China has yet to officially congratulate Joe Biden as the next US president, although many world leaders are already hailing a reset in US foreign policy. Many are wondering if this and other moves indicate a quiet internal shift for China's high tech and life sciences sectors, just days after Beijing concluded a high-level plenary meeting outlining its priorities for the next five years.
Topic US Election 2020 China
Scrip
By Brian Yang 26 Jun 2020
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
Scrip
By Brian Yang 20 May 2020
The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.
Topic Coronavirus
Scrip
By Brian Yang 20 Apr 2020
Gilead’s front-running antiviral to fight the coronavirus has shown rapid improvement in severe patients’ symptoms in one US study but some are not convinced.
Topic Coronavirus
Scrip
By Brian Yang 19 Mar 2020
Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.
Topic Coronavirus
Pink Sheet
By Brian Yang 18 Feb 2020
72 Products Approved Under Expanded Emergency Pathway A regulatory pathway set up in China post-SARS is under stress test in the latest coronavirus outbreak, while emergency measures adopted by the country's regulator mean it’s much less burdensome to obtain approvals than before.
Scrip
By Brian Yang 07 Feb 2020
Wuhan Institute of Pathology files patent over new use of Gilead's remdesivir and Regeneron expands collaboration with HHS to include 2019-nCoV.
Topic Coronavirus
Scrip
By Brian Yang 07 Feb 2020
China is tightening oversight over suspected coronavirus cases, allowing hospitals to quarantine patients upon their first visit as confirmed infections surpass 20,000. Domestic firm Ascletis has meanwhile filed for the emergency approval of its generic version of AbbVie's Norvir (ritonavir) and a novel combo therapy.
Topic Coronavirus
Scrip
By Brian Yang 07 Feb 2020
US antiviral specialist Gilead is working to provide its experimental drug remdesivir to treat the China coronavirus, while other potential treatments and alliances continue to emerge, including between Wuhan-based BravoVax and US venture GeoVax.
Topic Coronavirus
Scrip
By Brian Yang 18 Dec 2019
Join the Asia-based content team for Scrip and the Pink Sheet for their first podcast as they take a look at some of the most significant regional pharma stories of the past few weeks.
Topic Approvals Business Strategies
Pink Sheet
26 Jul 2022
Scrip
14 Jul 2022
Pink Sheet
07 Jul 2022
Scrip
06 Jul 2022
Pink Sheet
01 Jul 2022
Scrip
29 Jun 2022
Scrip
02 Jun 2022
Medtech Insight
31 May 2022
Scrip
30 May 2022
Scrip
20 May 2022
Pink Sheet
18 May 2022
Pink Sheet
12 May 2022
Scrip
11 May 2022
Pink Sheet
06 May 2022
Pink Sheet
29 Apr 2022
